神经内分泌肿瘤的检测：99mTc-P829闪烁扫描术与111In-奥曲肽闪烁扫描术的比较

Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.

作者信息

Lebtahi Rachida, Le Cloirec Joseph, Houzard Claire, Daou Doumit, Sobhani Iradj, Sassolas Geneviève, Mignon Michel, Bourguet Patrick, Le Guludec Dominique

机构信息

Nuclear Medicine Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France.

出版信息

J Nucl Med. 2002 Jul;43(7):889-95.

PMID:12097458

Abstract

UNLABELLED

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-pentetreotide.

METHODS

Forty-three patients (32 men, 11 women; age range, 24-78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 microg somatostatin analog labeled with 148 +/- 17 MBq 111In, and SPECT was performed 24 h after injection. Similar (99m)Tc-P829 planar images were obtained at 1, 4-6, and 24 h after injection of 50 microg peptide labeled with 991.6 +/- 187.59 MBq 99mTc. Abdominal SPECT was performed 4-6 h after injection.

RESULTS

111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P < 0.005). In the liver, 129 sites (in 24 patients) were detected by 111In-pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by 99mTc-P829 scintigraphy.

CONCLUSION

In patients with endocrine tumors, the detection rate of 99mTc-P829 scintigraphy was lower than that of 111In-pentetreotide scintigraphy, which appeared to be more sensitive, especially for liver metastases.

摘要

未标注

本研究旨在评估一种新的生长抑素类似物99mTc-P829与111In-奥曲肽相比的诊断价值。

方法

前瞻性纳入43例经生物学或组织学证实的神经内分泌肿瘤患者（32例男性，11例女性；年龄范围24 - 78岁，平均年龄56岁）：11例卓艾综合征患者，16例类癌患者，16例其他类型的功能性（n = 6）或非功能性（n = 10）内分泌肿瘤患者。注射10μg标记有148±17MBq 111In的生长抑素类似物后4小时和24小时获取111In-奥曲肽平面图像（头部、胸部、腹部和骨盆），注射后24小时进行单光子发射计算机断层扫描（SPECT）。注射50μg标记有991.6±187.59MBq 99mTc的肽后1小时、4 - 6小时和24小时获取类似的99mTc-P829平面图像。注射后4 - 6小时进行腹部SPECT。